CustomKinFragLib: Filtering the Kinase-Focused Fragmentation Library

10 June 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Protein kinases play a crucial role in key regulatory cell processes and are known to be dysregulated in diseases such as cancer and autoimmune disorders. Hence, protein kinases represent a vital drug target class. To meet the challenge of designing novel kinase inhibitors, fragment-based drug discovery (FBDD) has already shown great promise. The kinase-specific fragment library KinFragLib is a data-driven FBDD approach providing a powerful subpocket-specific framework for creating potentially feasible kinase inhibitors through subpocket-guided enumeration and combination of fragments. However, traversing the whole recombination space is computationally infeasible. Here, we present CustomKinFragLib, a fragment library reduction pipeline that builds onto KinFragLib. CustomKinFragLib considers several drug-relevant aspects, including synthesizability by filtering according to commercially available building blocks, calculating a synthetic accessibility score, and filtering for fragments with available retrosynthetic pathways. It also considers molecular properties often associated with drug-likeness and removes fragments containing unwanted substructures. Our new fragmentation library reduces KinFragLib from 9131 to 523 fragments while retaining diverse fragments with drug-like properties and high synthetic tractability. The code and dataset are available at https://github.com/volkamerlab/KinFragLib.

Keywords

Kinase inhibitors
Fragment-based drug design
KinFragLib

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.